1-8 of 8
David Stirling, PhD
Close
Sort by
Journal Articles

Cathepsin G, a Potent Platelet Aggregation Activator, Is Upregulated in Multiple Myeloma Patients during Treatment with Lenalidomide (Revlimid).

Rekha Pal, PhD, Ryan Kennedy, L. Renee Mansour, David Stirling, PhD, Markus Y. Mapara, MD, PhD, G. David Roodman, MD, PhD, Suzanne Lentzsch, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2504.
https://doi.org/10.1182/blood.V110.11.2504.2504
Published: 2007
Journal Articles

Microparticles (platelet, Endothelial, and Leucocyte) Are Elevated in Patients with Myeloproliferative Disorders.

Susan Lynch, MBChB, MRCP, David Stirling, PhD, Christopher A. Ludlam, FRCPath, PhD
Journal: Blood
Blood (2007) 110 (11): 1552.
https://doi.org/10.1182/blood.V110.11.1552.1552
Published: 2007
Journal Articles

Lenalidomide Enhancement of NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Is Mediated by Granzyme B and FasL and Is Associated with Modification of SHIP-1, PLC-g2 and pERK and Enhanced Chemokine Production.

Lei Wu, MD, Mary Adams, MS, Peter Schafer, PhD, George Muller, PhD, David Stirling, PhD, Blake J. Bartlett, PhD
Journal: Blood
Blood (2007) 110 (11): 4885.
https://doi.org/10.1182/blood.V110.11.4885.4885
Published: 2007
Journal Articles

Lenalidomide Displays Direct Anti-Non-Hodgkin’s Lymphoma (NHL) Cell Activity in Association with Enhanced SPARC Expression but Independent of Its Ability to Strongly Inhibit NHL Cell VEGF Production In Vitro .

Ling-Hua Zhang, PhD, Peter Schafer, PhD, George Muller, PhD, David Stirling, PhD, J. Blake Bartlett, PhD
Journal: Blood
Blood (2007) 110 (11): 3473.
https://doi.org/10.1182/blood.V110.11.3473.3473
Published: 2007
Journal Articles

Lenalidomide Strongly Enhances Natural Killer (NK) Cell Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) of Rituximab Treated Non-Hodkin’s Lymphoma Cell Lines In Vitro .

Lei Wu, MD, Peter Schafer, PhD, George Muller, PhD, David Stirling, PhD, J. Blake Bartlett, PhD
Journal: Blood
Blood (2006) 108 (11): 3714.
https://doi.org/10.1182/blood.V108.11.3714.3714
Published: 2006
Journal Articles

Comparison of Anti-Angiogenic Activities of Thalidomide and Lenalidomide In Vitro.

Ling-Hua Zhang, PhD, Ling Lu, MS, Lei Wu, MS, Keith Dredge, PhD, J. Blake Bartlett, PhD, Peter Schafer, PhD, George Muller, PhD, Angus Dalgleish, PhD, David Stirling, PhD
Journal: Blood
Blood (2005) 106 (11): 3959.
https://doi.org/10.1182/blood.V106.11.3959.3959
Published: 2005
Journal Articles

Thalidomide Derivative CC-4047 Inhibits Osteoclast Formation by down Regulation of PU.1.

Suzanne Lentzsch, MD, PhD, Gulsum Anderson, PhD, Noriyoshi Kurihara, DDS, PhD, Tadashi Honjo, DDS, PhD, Judith Anderson, Markus Y. Mapara, MD, PhD, David Stirling, PhD, David Roodman, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 629.
https://doi.org/10.1182/blood.V106.11.629.629
Published: 2005
Journal Articles

Effect of Thalidomide and Revlimid on the Gene Expression That Reveals Molecular Circuitries Involved in T Cell Co-Activation.

Rao Prabhala, PhD, Puneet Cheema, MD, Masood A. Shammas, PhD, Weihua Song, PhD, Elizabeth Blanchard, MD, Dharminder Chauhan, PhD, Paola Neri, MD, Pierfrancesco Tassone, MD, David Stirling, PhD, Kenneth Anderson, MD, Nikhil C. Munshi, MD
Journal: Blood
Blood (2004) 104 (11): 2472.
https://doi.org/10.1182/blood.V104.11.2472.2472
Published: 2004